StockNews.AI
BGNE
StockNews.AI
112 days

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

1. BeiGene's patent challenge against Pharmacyclics was successful. 2. The company plans to rename itself BeOne Medicines Ltd.

2m saved
Insight
Article

FAQ

Why Bullish?

The invalidation of the patent strengthens BeiGene's market position. Historically, patent victories can lead to increased stock prices in biotech.

How important is it?

The patent invalidation enhances BeiGene's business prospects, influencing investor confidence.

Why Short Term?

The news likely impacts investor sentiment quickly due to patent significance in biotech.

Related Companies

PCYCMRNANVDA
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC's (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR pe.

Related News